Watch AIDX. Know when insiders buy.
One email the day a filing lands. Free.
AIDX
20/20 Biolabs, Inc.
0.27
+0.00 +0.07%
USD · close Oct 21
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
81
PASS · shorts 81
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $3.5MP/E —DIV YIELD —FCF YIELD —REV TTM $2M +16.7%NET INCOME −$3.7MNET CASH —52W 0.26 – 23.85SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $731K | — | 41.7% | −$1.2M | −$1.5M | — | -0.26 | −$605K | — | — | Aug 14 |
| Q1 2026 · Mar 31 | $353K | — | 17.8% | −$1.4M | −$2.2M | — | -0.28 | −$1.3M | — | — | Aug 14 |
| Q2 2025 · Jun 30 | $535K | — | 30.5% | −$846K | −$841K | — | -0.17 | −$534K | — | — | Aug 14 |
| Q1 2025 · Mar 31 | $554K | — | 29.9% | −$772K | −$765K | — | -0.16 | −$488K | — | — | Aug 14 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $2M | 29.6% | −$3.3M | −$3.7M | -182.8% | -0.76 | −$1.9M | — | — | — | — |
| FY2024 · to Dec 31 | $1.8M | 20.6% | −$5.7M | −$5.6M | -316.8% | -1.16 | −$2.6M | — | — | — | — |
Every number comes from 20/20 Biolabs, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.